Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$0.38 - $0.91 $10,602 - $25,389
-27,900 Reduced 53.65%
24,100 $21,000
Q3 2023

Nov 07, 2023

BUY
$0.79 - $2.83 $41,080 - $147,160
52,000 New
52,000 $44,000
Q1 2023

May 12, 2023

BUY
$15.95 - $25.18 $271,086 - $427,959
16,996 New
16,996 $317,000
Q2 2022

Aug 09, 2022

BUY
$7.94 - $12.96 $29,735 - $48,535
3,745 New
3,745 $39,000
Q4 2021

Feb 11, 2022

SELL
$9.93 - $15.39 $132,029 - $204,625
-13,296 Closed
0 $0
Q3 2021

Nov 09, 2021

BUY
$10.18 - $26.64 $135,353 - $354,205
13,296 New
13,296 $135,000
Q2 2021

Aug 12, 2021

SELL
$18.57 - $35.68 $124,177 - $238,592
-6,687 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$31.0 - $55.72 $207,297 - $372,599
6,687 New
6,687 $232,000
Q4 2020

Feb 12, 2021

SELL
$37.09 - $48.97 $110,008 - $145,245
-2,966 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$40.47 - $45.5 $47,835 - $53,781
1,182 Added 66.26%
2,966 $121,000
Q2 2020

Aug 13, 2020

BUY
$32.57 - $42.83 $58,104 - $76,408
1,784 New
1,784 $72,000
Q1 2020

May 13, 2020

SELL
$23.3 - $45.96 $76,820 - $151,530
-3,297 Closed
0 $0
Q4 2019

Feb 10, 2020

BUY
$34.58 - $48.06 $64,560 - $89,728
1,867 Added 130.56%
3,297 $141,000
Q3 2019

Nov 12, 2019

BUY
$36.98 - $48.45 $52,881 - $69,283
1,430 New
1,430 $52,000
Q4 2018

Feb 13, 2019

SELL
$37.97 - $60.16 $29,160 - $46,202
-768 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$56.3 - $67.25 $23,477 - $28,043
-417 Reduced 35.19%
768 $46,000
Q2 2018

Aug 13, 2018

BUY
$44.9 - $64.95 $53,206 - $76,965
1,185 New
1,185 $74,000
Q4 2017

Feb 12, 2018

SELL
$41.95 - $60.1 $1,426 - $2,043
-34 Closed
0 $0
Q3 2017

Nov 07, 2017

BUY
$33.4 - $53.9 $1,135 - $1,832
34
34 $1,000

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.